Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Am J Obstet Gynecol ; 188(6): 1438-4; discussion 1444-6, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12824976

RESUMO

OBJECTIVE: The purpose of this study was to compare interleukin-6 and funisitis as predictors of impaired neurologic outcomes in children by performing a secondary analysis on data that were collected prospectively for another purpose. STUDY DESIGN: We examined umbilical cords for funisitis and obtained cord blood for interleukin-6 levels. A psychomotor developmental index score was determined for each child at age 18 months. RESULTS: The prevalence (46%) of elevated interleukin-6 levels (> or = 10 pg/mL) among children with low psychomotor developmental index scores (<100) was not significantly different from that of children with normal scores (47%). Among children with funisitis (n = 21), the median psychomotor developmental index score was 94; for children without funisitis (n = 92), it was 99 (P <.02). When the data were regressed for confounding, funisitis remained significant (adjusted odds ratio, 1.3; 95% CI, 1.1-1.9). Furthermore, funisitis was a more specific predictor of low psychomotor developmental index scores (P <.001), although elevated interleukin-6 levels were more sensitive. CONCLUSION: When used for the prediction of impaired neurologic outcomes in children, funisitis has better specificity and thus a better positive predictive value than does interleukin-6.


Assuntos
Paralisia Cerebral/etiologia , Doenças Fetais/imunologia , Inflamação/imunologia , Interleucina-6/imunologia , Cordão Umbilical , Adulto , Paralisia Cerebral/congênito , Feminino , Sangue Fetal , Humanos , Lactente , Recém-Nascido , Inflamação/complicações , Interleucina-6/sangue , Masculino , Valor Preditivo dos Testes , Gravidez , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Sensibilidade e Especificidade
4.
Am J Obstet Gynecol ; 186(6): 1111-8, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12066082

RESUMO

OBJECTIVE: The purpose of this study was to determine whether the use of antenatal magnesium sulfate prevents adverse outcomes (neonatal intraventricular hemorrhage, periventricular leucomalacia, death, and cerebral palsy). STUDY DESIGN: In a controlled trial, we randomized mothers in preterm labor to magnesium sulfate, "other" tocolytic, or placebo. At delivery, umbilical cord blood was collected for the later determination of serum ionized magnesium levels. Neonatal cranial ultrasound scans were obtained periodically for the diagnosis of intraventricular hemorrhage and periventricular leucomalacia. Among survivors, the diagnosis of cerebral palsy was made at age 18 months. RESULTS: Children with adverse outcomes had higher umbilical cord magnesium levels at delivery. In regression models that controlled for confounders, which included very low birth weight, magnesium remained a significant risk factor (adjusted odds ratio, 3.7; 95% CI, 1.1-11.9; P =.03). CONCLUSION: Contrary to original hypotheses, this randomized trial found that the use of antenatal magnesium sulfate was associated with worse, not better, perinatal outcome in a dose-response fashion.


Assuntos
Hemorragia Cerebral/induzido quimicamente , Paralisia Cerebral/induzido quimicamente , Mortalidade Infantil , Leucomalácia Periventricular/induzido quimicamente , Sulfato de Magnésio/efeitos adversos , Trabalho de Parto Prematuro/tratamento farmacológico , Cuidado Pré-Natal , Tocolíticos/efeitos adversos , Adulto , Feminino , Sangue Fetal , Humanos , Recém-Nascido , Trabalho de Parto , Magnésio/sangue , Sulfato de Magnésio/uso terapêutico , Gravidez , Fatores de Risco , Tocolíticos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA